Laquinimod, Huntington's disease, and disease modification
- PMID: 38280390
- DOI: 10.1016/S1474-4422(24)00001-2
Laquinimod, Huntington's disease, and disease modification
Conflict of interest statement
TAM reports speaker honorarium from Abbvie and International Parkinson and Movement Disorder Society; consultancies from CHDI Foundation/Management, Roche, and Abbvie; and research funding from EU Joint Programme—Neurodegenerative Disease Research, uOBMRI, Roche, Ontario Research Fund, Canadian Institutes of Health Research, The Michael J Fox Foundation, Parkinson Canada, and Parkinson Research Consortium.
Comment on
-
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.Lancet Neurol. 2024 Mar;23(3):243-255. doi: 10.1016/S1474-4422(23)00454-4. Epub 2024 Jan 24. Lancet Neurol. 2024. PMID: 38280392 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
